Skip to main content
TipRanks
Go Ultimate75% OFF

Clover Health Investments (CLOV) AI Stock Analysis

3,669 Followers
CLOV

Clover Health Investments

(NASDAQ:CLOV)

Select Model
Rating:67Neutral
Price Target:$5.50▲(11.11% Upside)
Action:reiterated
Date:11/05/26

The score is driven primarily by improving financial performance (turnaround to positive TTM earnings, strong cash-flow rebound, and no debt) and a bullish, guidance-raising earnings call that supports continued growth and profitability. These positives are tempered by a demanding valuation (very high P/E) and only mixed technical momentum signals.

Positive Factors
Membership and earnings growthRapid membership and revenue growth, combined with the expected first full year of GAAP profitability, indicates meaningful operating progress. A larger insured base can support stronger purchasing scale, while improving earnings provide greater capacity to reinvest in care delivery, technology, and market expansion.
Negative Factors
Thin and unproven marginsAlthough profitability has recently turned positive, sub-1% net margins leave little room for unfavorable medical-cost or expense movements. The improving trend is not yet a durable earnings cushion, so sustained margin expansion remains important for converting growth into consistent shareholder returns.

Clover Health Investments Key Performance Indicators (KPIs)

Revenue by SegmentSeparates revenue into lines like Medicare Advantage premiums versus platform or services revenue. Identifies which activities drive top-line growth and which deliver higher margins. A shift toward service or platform revenue can improve profitability and diversify risk, whereas dependence on premium revenue makes results more sensitive to medical costs and regulatory changes.

$0.00$200.00M$400.00M$600.00M$800.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

Clover has shifted from a mix of non‑insurance and premium revenue to being overwhelmingly premium‑driven: Non‑Insurance Revenue collapsed to zero after 2023 (likely one‑offs or discontinued activities), while Premiums Earned surged in 2025, signaling membership/market share growth. That improves top‑line predictability but concentrates risk on medical cost trends and Medicare policy/underwriting performance. The small, volatile “Other” line (notably the Sept‑2025 spike) looks like a one‑time item—track margins and guidance to judge whether higher premiums convert to durable profit.

Data provided by:The Fly

Clover Health Investments (CLOV) vs. SPDR S&P 500 ETF (SPY)

-50%-25%0%25%50%75%100%125%150%CLOV+113.36%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$2.63B
Dividend Yield
―
Average Volume (3M)
4.26M
Price to Earnings (P/E)
289.1
Beta (1Y)
1.44
Revenue Growth
54.46%
EPS Growth
―
Country
US
Employees
724
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Plans

Clover Health Investments Business Overview & Revenue Model

Company Description

Clover Health Investments, Corp. is a U.S.-based firm specializing in Medicare Advantage insurance. The company leverages its proprietary software platform, the Clover Assistant, to provide both Preferred Provider Organization (PPO) and Health Mainte...

How the Company Makes Money

Clover Health primarily makes money by operating Medicare Advantage (MA) plans and earning premium revenue that is largely funded by the U.S. government (Centers for Medicare & Medicaid Services, CMS). For each enrolled member, Clover receives a per-...

Clover Health Investments Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:5.54%|Next Earnings Date:Mar 04, 2027
Earnings Call SentimentPositive

The call was strongly positive, with substantial membership, revenue, gross profit, EBITDA and net income growth; improved full-year guidance; expected first full-year GAAP profitability; leading Star Ratings and HEDIS performance; favorable cohort economics; and encouraging early 2027 enrollment results. The company also identified meaningful earnings expansion opportunities from cohort maturation and operating leverage. Offsetting issues included elevated outpatient utilization, a planned seasonal fourth-quarter EBITDA loss, a near-term earnings drag from new members, a pending government appeal and management's criticism of the current Stars measurement framework.

Positive Updates

Expected First Full Year of GAAP Profitability
Clover expects to deliver its first full year of GAAP net income profitability in 2026. Through the first nine months, GAAP net income improved by nearly $100 million, and year-to-date GAAP net income increased by $98 million to $62 million.

Negative Updates

Elevated Outpatient Utilization
Although inpatient utilization trends were favorable, outpatient utilization remained elevated year-over-year. Management said the increase was in line with its initial outlook.

Company Guidance

For full year 2026, Clover expects average Medicare Advantage membership of 157,000 to 158,000 members, total revenue of $2.97 billion to $3 billion, consolidated gross profit of $540 million to $555 million, adjusted EBITDA of $75 million to $85 million and GAAP net income of $25 million to $35 million; for the full year, it expects adjusted SG&A ratio improvement at or above its original target of 100 basis points to 150 basis points, while the fourth quarter is expected to include lower consolidated gross profit from normal medical cost seasonality, higher SG&A as planned AEP investments increase and the seasonal adjusted EBITDA loss already contemplated in guidance. Clover is not providing formal guidance for 2027 or 2028, but expects another strong year of membership growth, meaningful earnings expansion in 2027 and momentum into 2028, with insurance gross profit per member per month approximately $70 higher in year 2 than in year 1 and approximately $85 higher in year 3 than in year 2; approximately half of current membership comprises the 2025 and 2026 cohorts, with 21% of members in their second year this year and 28% in year 1.

Clover Health Investments Financial Statement Overview

Summary

Financials reflect a clear turnaround: strong TTM revenue growth (10.6%), a move to modest TTM net income (~$12.5M), zero debt with rebuilding equity, and a sharp rebound in operating/free cash flow (OCF ~$135.3M; FCF ~$132.3M). The main constraint is durability—net margins are still very thin and cash flows have been historically volatile, leaving results sensitive to medical-cost and expense swings.

Income Statement

62Positive

Balance Sheet

70Positive

Cash Flow

73Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.74B1.92B1.37B1.26B1.10B1.47B
Gross Profit516.60M355.88M364.80M255.95M103.48M-79.18M
EBITDA14.56M-83.86M-44.94M-207.63M-252.03M-569.60M
Net Income12.45M-85.55M-43.01M-213.36M-339.57M-587.76M
Balance Sheet
Total Assets753.68M541.01M580.74M570.67M808.62M950.80M
Cash, Cash Equivalents and Short-Term Investments272.58M95.35M221.54M242.69M334.76M615.25M
Total Debt0004.66M5.86M27.83M
Total Liabilities362.81M232.31M239.60M284.28M451.73M411.49M
Stockholders Equity390.87M308.70M341.14M286.39M356.89M535.41M
Cash Flow
Free Cash Flow132.28M-68.98M33.29M-116.45M-208.39M-283.05M
Operating Cash Flow135.31M-66.93M34.84M-115.87M-203.93M-282.33M
Investing Cash Flow-42.97M4.08M565.00K140.01M95.13M-435.45M
Financing Cash Flow-14.33M-53.38M-17.36M-33.86M-4.96M925.39M

Clover Health Investments Technical Analysis

Technical Analysis SentimentPositive
Last Price4.95

Price Trends

50DMA4.62Positive
100DMA4.57Positive
200DMA3.67Positive

Market Momentum

MACD0.10Negative
RSI58.28Neutral
STOCH66.15Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLOV, the sentiment is Positive. The current price of 4.95 is above the 20-day moving average (MA) of 4.70, above the 50-day MA of 4.62, and above the 200-day MA of 3.67, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 58.28 is Neutral, neither overbought nor oversold. The STOCH value of 66.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLOV.

Clover Health Investments Risk Analysis

Clover Health Investments disclosed 67 risk factors in its most recent earnings report. Clover Health Investments reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Our failure to protect our sites, networks, and systems against security breaches, or otherwise to protect our confidential or health information or the confidential or health information of our members, providers, or other third parties, could damage our reputation and brands, and substantially harm our business and results of operations.Q2, 2026
2.Our failure to satisfy NASDAQ's continued listing standards could result in a delisting of our Class A common stock, which could limit investors' ability to make transactions in our Class A common stock and subject us to additional trading restrictions.Q4, 2024
3.Although our share repurchase program is intended to enhance long-term shareholder value, we cannot provide assurance that this will occur, and this program may be suspended or terminated at any time.Q4, 2024

Clover Health Investments Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CLOV against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ELVELV76Outperform$96.42B18.9711.59%1.54%3.60%-4.06%
CLOVCLOV67Neutral$2.63B289.123.52%―54.46%―
CNCCNC66Neutral$37.02B25.266.78%―9.71%―
UNHUNH62Neutral$369.18B23.3916.35%2.20%3.33%-8.75%
ALHCALHC60Neutral$1.56B52.4512.46%―35.87%―
HUMHUM58Neutral$55.40B44.416.70%0.77%22.02%-3.07%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%CLOVCNCHUMUNHELVALHCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CLOV and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CLOVClover Health Investments Corp4.952.60110.64%
CNCCentene74.7737.84102.46%
HUMHumana461.25230.1799.60%
UNHUnitedhealth Group Inc.412.02106.5734.89%
ELVElevance Health, Inc.446.28128.0840.25%
ALHCAlignment Healthcare, Inc.7.47-8.63-53.60%

Clover Health Investments Corporate Events

Business Operations and StrategyFinancial Disclosures

Clover Health Releases Supplemental Shareholder Q&A Responses

Neutral
Nov 17, 2026

On November 16, 2026, Clover Health published supplemental responses to selected shareholder questions submitted in connection with its third-quarter 2026 earnings announcement. The Q&A addressed the company’s business scale, operating expenses, Coun...

Executive/Board ChangesFinancial Disclosures

Clover Health Reports Strong Third-Quarter Results and Growth

Positive
Nov 4, 2026

On November 2, 2026, Clover’s board appointed interim Chief Financial Officer Clay Thornton to the position permanently and named Vice President and Controller Joseph Oldakowski chief accounting officer, effective November 4. Their new agreements pro...

Business Operations and StrategyLegal Proceedings

Clover Health Earns Top CMS Star Ratings for 2027

Positive
Oct 9, 2026

On October 8, 2026, Clover Health announced that the Centers for Medicare & Medicaid Services awarded its PPO Medicare Advantage plans a 5-Star rating and its HMO plan a 4.5-Star rating for the 2027 measurement year, which will drive 2028 payment lev...

Business Operations and StrategyExecutive/Board Changes

Clover Health Adds Policy and Clinical Experts to Board

Positive
Sep 24, 2026

On September 22, 2026, Clover Health Investments appointed former U.S. Senator Robert G. Torricelli and MedPAC Commissioner Dr. Brian J. Miller to its Board of Directors, filling two previously disclosed vacancies and expanding the Board to nine memb...

Business Operations and StrategyFinancial Disclosures

Clover Health Highlights Depth-Focused Strategy and Technology Investments

Positive
Aug 20, 2026

On August 20, 2026, Clover Health released a supplemental Q&A tied to its second-quarter 2026 earnings, aiming to deepen engagement with shareholders and clarify its operating model and outlook. Management highlighted how its Clover Assistant-driven...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026